{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:57:57Z","timestamp":1790819877526,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"DOI":"10.1007\/s40273-026-01648-7","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:58:37Z","timestamp":1785301117000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Machine Learning and Large Language Model Tool for Systematic Literature Reviews of Health Economic Evidence: A Validation Study"],"prefix":"10.1007","author":[{"given":"Lisa M.","family":"Bloudek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8528-9901","authenticated-orcid":false,"given":"Allie B.","family":"Cichewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kush","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean D.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5439-4074","authenticated-orcid":false,"given":"Kevin M.","family":"Kallmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"1648_CR1","unstructured":"NICE. NICE technology appraisal and highly specialised technologies guidance: the manual. PMG36. Published: 31 January 2022; updated: 17 December 2025. Available from: https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/evidence-2. Accessed 24 Jul 2026."},{"issue":"2","key":"1648_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012545","volume":"7","author":"R Borah","year":"2017","unstructured":"Borah R, Brown AW, Capers PL, Kaiser KA. Analysis of the time and workers needed to conduct systematic reviews of medical interventions using data from the PROSPERO registry. BMJ Open. 2017;7(2):e012545. https:\/\/doi.org\/10.1136\/bmjopen-2016-012545.","journal-title":"BMJ Open"},{"key":"1648_CR3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jclinepi.2020.01.008","volume":"121","author":"J Clark","year":"2020","unstructured":"Clark J, Glasziou P, Del Mar C, Bannach-Brown A, Stehlik P, Scott AM. A full systematic review was completed in 2 weeks using automation tools: a case study. J Clin Epidemiol. 2020;121:81\u201390. https:\/\/doi.org\/10.1016\/j.jclinepi.2020.01.008.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"1648_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.mcpdig.2024.05.023","volume":"2","author":"IB Riaz","year":"2024","unstructured":"Riaz IB, Naqvi SAA, Hasan B, Murad MH. Future of evidence synthesis: automated, living, and interactive systematic reviews and meta-analyses. Mayo Clin Proc Digit Health. 2024;2(3):361\u20135. https:\/\/doi.org\/10.1016\/j.mcpdig.2024.05.023.","journal-title":"Mayo Clin Proc Digit Health"},{"issue":"4","key":"1648_CR5","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/jamia\/ocaf030","volume":"32","author":"Y Li","year":"2025","unstructured":"Li Y, Datta S, Rastegar-Mojarad M, et al. Enhancing systematic literature reviews with generative artificial intelligence: development, applications, and performance evaluation. J Am Med Inform Assoc. 2025;32(4):616\u201325. https:\/\/doi.org\/10.1093\/jamia\/ocaf030.","journal-title":"J Am Med Inform Assoc"},{"issue":"1","key":"1648_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-025-02997-8","volume":"15","author":"J Zhan","year":"2025","unstructured":"Zhan J, Suvada K, Xu M, et al. Accelerating the pace and accuracy of systematic reviews using AI: a validation study. Syst Rev. 2025;15(1):24. https:\/\/doi.org\/10.1186\/s13643-025-02997-8.","journal-title":"Syst Rev"},{"issue":"3","key":"1648_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s40273-019-00878-2","volume":"38","author":"E Jacobsen","year":"2020","unstructured":"Jacobsen E, Boyers D, Avenell A. Challenges of systematic reviews of economic evaluations: a review of recent reviews and an obesity case study. Pharmacoeconomics. 2020;38(3):259\u201367. https:\/\/doi.org\/10.1007\/s40273-019-00878-2.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1648_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-025-02519-z","volume":"25","author":"Y Xin","year":"2025","unstructured":"Xin Y, Song R, Hao J, et al. Poor reporting quality and high proportion of missing data in economic evaluations alongside pragmatic trials: a cross-sectional survey. BMC Med Res Methodol. 2025;25(1):61. https:\/\/doi.org\/10.1186\/s12874-025-02519-z.","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"1648_CR9","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1093\/jamia\/ocaf063","volume":"32","author":"DDA Bui","year":"2025","unstructured":"Bui DDA, Schneider J, Riley E, et al. The emergence of large language models as tools in literature reviews: a large language model-assisted systematic review. J Am Med Inform Assoc. 2025;32(6):1071\u201386. https:\/\/doi.org\/10.1093\/jamia\/ocaf063.","journal-title":"J Am Med Inform Assoc"},{"key":"1648_CR10","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s13643-024-02609-x","volume":"13","author":"Q Khraisha","year":"2024","unstructured":"Khraisha Q, Put S, Kappenberg J, Warraitch A, Hadfield K. Can large language models replace humans in systematic reviews? Evaluating GPT-4\u2019s efficacy in screening and extracting data from peer-reviewed and grey literature in multiple languages. Syst Rev. 2024;13:158. https:\/\/doi.org\/10.1186\/s13643-024-02609-x.","journal-title":"Syst Rev"},{"key":"1648_CR11","doi-asserted-by":"publisher","unstructured":"Schmidt L, Sinyor E, Webb-Liddal H, et al. Exploring the use of a large language model for data extraction in systematic reviews: a rapid feasibility study. arXiv. 2024. https:\/\/doi.org\/10.48550\/arXiv.2405.14445.","DOI":"10.48550\/arXiv.2405.14445"},{"issue":"10209","key":"1648_CR12","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(19)31881-1.","journal-title":"Lancet"},{"issue":"10","key":"1648_CR13","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","volume":"9","author":"JK Han","year":"2021","unstructured":"Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(10):1141\u201353. https:\/\/doi.org\/10.1016\/S2213-2600(21)00097-7.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"1648_CR14","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","volume":"146","author":"P Gevaert","year":"2020","unstructured":"Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595\u2013605. https:\/\/doi.org\/10.1016\/j.jaci.2020.05.032.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1648_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/cesm.70059","volume":"3","author":"KM Kallmes","year":"2025","unstructured":"Kallmes KM, Thurnham J, Sauca M, Tarchand R, Kallmes KR, Holub KJ. Human-in-the-loop artificial intelligence system for systematic literature review: methods and validations for the AutoLit Review software. Cochrane Evid Synth Methods. 2025;3(6):e70059. https:\/\/doi.org\/10.1002\/cesm.70059.","journal-title":"Cochrane Evid Synth Methods."},{"issue":"1","key":"1648_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227742","volume":"15","author":"Z Wang","year":"2020","unstructured":"Wang Z, Nayfeh T, Tetzlaff J, O\u2019Blenis P, Murad MH. Error rates of human reviewers during abstract screening in systematic reviews. PLoS ONE. 2020;15(1):e0227742. https:\/\/doi.org\/10.1371\/journal.pone.0227742.","journal-title":"PLoS ONE"},{"issue":"2","key":"1648_CR17","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1177\/0049124118799372","volume":"50","author":"J Belur","year":"2018","unstructured":"Belur J, Tompson L, Thornton A, Simon M. Interrater reliability in systematic review methodology: exploring variation in coder decision-making. Sociol Methods Res. 2018;50(2):837\u201365. https:\/\/doi.org\/10.1177\/0049124118799372.","journal-title":"Sociol Methods Res"},{"issue":"1","key":"1648_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-017-0431-4","volume":"17","author":"T Mathes","year":"2017","unstructured":"Mathes T, Kla\u00dfen P, Pieper D. Frequency of data extraction errors and methods to increase data extraction quality: a methodological review. BMC Med Res Methodol. 2017;17(1):152. https:\/\/doi.org\/10.1186\/s12874-017-0431-4.","journal-title":"BMC Med Res Methodol"},{"key":"1648_CR19","doi-asserted-by":"publisher","first-page":"S720","DOI":"10.1016\/j.jval.2020.08.1904","volume":"23","author":"C Jommi","year":"2020","unstructured":"Jommi C, Fanelli F, Pedone M, Cipriani F, Canonica G. PRS24 the CROSS-coverage effect of dupilumab in treating coexisting type 2 inflammatory diseases on the Italian National Health Service expenditure. Value Health. 2020;23:S720\u20131. https:\/\/doi.org\/10.1016\/j.jval.2020.08.1904.","journal-title":"Value Health"},{"key":"1648_CR20","unstructured":"Canada\u2019s Drug Agency - L\u2019Agence des m\u00e9dicaments du Canada. CADTH reimbursement recommendation: mepolizumab (Nucala) for severe chronic rhinosinusitis with nasal polyps. December 2022;2(12). Available from: https:\/\/www.cda-amc.ca\/sites\/default\/files\/DRR\/2022\/SR0735%20Nucala%20-%20CADTH%20Final%20Recommendation%20(with%20corrections)_Final.pdf. Accessed 13 Jan 2026."},{"issue":"5","key":"1648_CR21","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1080\/14737167.2023.2196407","volume":"23","author":"L Alvarez","year":"2023","unstructured":"Alvarez L, Querubin J, Bedoya J, Mejia A, S\u00e1nchez J. Cost-utility analysis of dupilumab compared with endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyps: evaluation in Colombia, a developing country. Expert Rev Pharmacoecon Outcomes Res. 2023;23(5):571\u20138. https:\/\/doi.org\/10.1080\/14737167.2023.2196407.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6","key":"1648_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12060951","volume":"12","author":"E De Corso","year":"2022","unstructured":"De Corso E, Furneri G, Salsi D, et al. Cost-utility analysis of dupilumab for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in Italy. J Pers Med. 2022;12(6):951. https:\/\/doi.org\/10.3390\/jpm12060951.","journal-title":"J Pers Med"},{"issue":"12","key":"1648_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.10.630","volume":"27","author":"L Dreyfus","year":"2024","unstructured":"Dreyfus L, Tavi J, Msihid J, Trindade C, Wang Z, Gandhi A. EE348 number needed to treat and cost-per-responder analysis of dupilumab and mepolizumab in chronic rhinosinusitis with nasal polyps. Value Health. 2024;27(12):S123. https:\/\/doi.org\/10.1016\/j.jval.2024.10.630.","journal-title":"Value Health"},{"issue":"12","key":"1648_CR24","doi-asserted-by":"publisher","first-page":"S200","DOI":"10.1016\/j.jval.2024.10.1018","volume":"27","author":"G Furneri","year":"2024","unstructured":"Furneri G, Tavi J, Joulain F, et al. EE738 Economic value of dupilumab and advanced therapeutics in patients with type 2 inflammatory diseases in Italy: an estimation of healthcare resource utilization cost offsets. Value Health. 2024;27(12):S200. https:\/\/doi.org\/10.1016\/j.jval.2024.10.1018.","journal-title":"Value Health"},{"issue":"4","key":"1648_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14040347","volume":"14","author":"I La Mantia","year":"2024","unstructured":"La Mantia I, Ottaviano G, Ragusa M, et al. Multidimensional impact of dupilumab on chronic rhinosinusitis with nasal polyps: a complete health technology assessment of clinical, economic, and non-clinical domains. J Pers Med. 2024;14(4):347. https:\/\/doi.org\/10.3390\/jpm14040347.","journal-title":"J Pers Med"},{"issue":"6","key":"1648_CR26","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/alr.22936","volume":"12","author":"A Parasher","year":"2022","unstructured":"Parasher A, Gliksman M, Segarra D, Lin T, Rudmik L, Quast T. Economic evaluation of dupilumab versus endoscopic sinus surgery for the treatment of chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2022;12(6):813\u201320. https:\/\/doi.org\/10.1002\/alr.22936.","journal-title":"Int Forum Allergy Rhinol"},{"issue":"1","key":"1648_CR27","doi-asserted-by":"publisher","first-page":"E26","DOI":"10.1002\/lary.28648","volume":"131","author":"G Scangas","year":"2021","unstructured":"Scangas G, Wu A, Ting J, et al. Cost utility analysis of dupilumab versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps. Laryngoscope. 2021;131(1):E26-33. https:\/\/doi.org\/10.1002\/lary.28648.","journal-title":"Laryngoscope"},{"issue":"12","key":"1648_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.09.669","volume":"26","author":"A Upegui","year":"2023","unstructured":"Upegui A, Cadena P, Pati\u00f1o G, Londono S. EE403 Economic analysis of dupilumab use in patients with chronic rhinosinusitis with nasal polyps in Colombia. Value Health. 2023;26(12):S128. https:\/\/doi.org\/10.1016\/j.jval.2023.09.669.","journal-title":"Value Health"},{"issue":"12","key":"1648_CR29","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/alr.22865","volume":"11","author":"M Yong","year":"2021","unstructured":"Yong M, Wu Y, Howlett J, Ballreich J, Walgama E, Thamboo A. Cost-effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease. Int Forum Allergy Rhinol. 2021;11(12):1626\u201336. https:\/\/doi.org\/10.1002\/alr.22865.","journal-title":"Int Forum Allergy Rhinol"},{"issue":"1","key":"1648_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-023-00823-1","volume":"19","author":"M Yong","year":"2023","unstructured":"Yong M, Kirubalingam K, Desrosiers M, Kilty S, Thamboo A. Cost-effectiveness analysis of biologics for the treatment of chronic rhinosinusitis with nasal polyps in Canada. Allergy Asthma Clin Immunol. 2023;19(1):90. https:\/\/doi.org\/10.1186\/s13223-023-00823-1.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"9","key":"1648_CR31","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1080\/14737167.2023.2234639","volume":"23","author":"MJ Oude Wolcherink","year":"2023","unstructured":"Oude Wolcherink MJ, Pouwels XGLV, van Dijk SHB, Doggen CJM, Koffijberg H. Can artificial intelligence separate the wheat from the chaff in systematic reviews of health economic articles? Expert Rev Pharmacoecon Outcomes Res. 2023;23(9):1049\u201356. https:\/\/doi.org\/10.1080\/14737167.2023.2234639.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6","key":"1648_CR32","doi-asserted-by":"publisher","first-page":"791","DOI":"10.7326\/M23-3389","volume":"177","author":"VT Tran","year":"2024","unstructured":"Tran VT, Gartlehner G, Yaacoub S, et al. Sensitivity and specificity of using GPT-3.5 Turbo models for title and abstract screening in systematic reviews and meta-analyses. Ann Intern Med. 2024;177(6):791\u20139. https:\/\/doi.org\/10.7326\/M23-3389.","journal-title":"Ann Intern Med"},{"key":"1648_CR33","doi-asserted-by":"publisher","DOI":"10.2196\/52758","volume":"26","author":"K Matsui","year":"2024","unstructured":"Matsui K, Utsumi T, Aoki Y, Maruki T, Takeshima M, Takaesu Y. Human-comparable sensitivity of large language models in identifying eligible studies through title and abstract screening: 3-layer strategy using GPT-GPT-3.5 and GPT-4 for systematic reviews. J Med Internet Res. 2024;26:e52758. https:\/\/doi.org\/10.2196\/52758.","journal-title":"J Med Internet Res"},{"issue":"6 Suppl.","key":"1648_CR34","doi-asserted-by":"publisher","first-page":"S318","DOI":"10.1016\/j.jval.2024.03.1576","volume":"27","author":"H Rathi","year":"2024","unstructured":"Rathi H, et al. Use of large language model (LLM) for full-text screening in systematic literature reviews: a comparative analysis. Value Health. 2024;27(6 Suppl.):S318. https:\/\/doi.org\/10.1016\/j.jval.2024.03.1576.","journal-title":"Value Health."},{"issue":"3","key":"1648_CR35","doi-asserted-by":"publisher","first-page":"389","DOI":"10.7326\/ANNALS-24-02189","volume":"178","author":"C Cao","year":"2025","unstructured":"Cao C, Sang J, Arora R, et al. Development of prompt templates for large language model-driven screening in systematic reviews. Ann Intern Med. 2025;178(3):389\u2013401. https:\/\/doi.org\/10.7326\/ANNALS-24-02189.","journal-title":"Ann Intern Med"},{"key":"1648_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-025-02583-5","volume":"25","author":"F Trad","year":"2025","unstructured":"Trad F, et al. Streamlining systematic reviews with large language models using prompt engineering and retrieval augmented generation. BMC Med Res Methodol. 2025;25:130. https:\/\/doi.org\/10.1186\/s12874-025-02583-5.","journal-title":"BMC Med Res Methodol"},{"key":"1648_CR37","doi-asserted-by":"publisher","first-page":"1117462024","DOI":"10.1016\/j.jclinepi.2024.111486","volume":"181","author":"JL Lieberum","year":"2025","unstructured":"Lieberum JL, Toews M, Metzendorf M. Large language models for conducting systematic reviews: on the rise, but not yet ready for use: a scoping review. J Clin Epidemiol. 2025;181:1117462024. https:\/\/doi.org\/10.1016\/j.jclinepi.2024.111486.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"1648_CR38","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1017\/rsm.2025.16","volume":"16","author":"J Clark","year":"2025","unstructured":"Clark J, Barton B, Albarqouni L, et al. Generative artificial intelligence use in evidence synthesis: a systematic review. Res Synth Methods. 2025;16(4):601\u201319. https:\/\/doi.org\/10.1017\/rsm.2025.16.","journal-title":"Res Synth Methods"},{"key":"1648_CR39","unstructured":"National Institute for Health and Care Excellence. Use of AI in evidence generation: NICE position statement. 2024. Available from: https:\/\/www.nice.org.uk\/corporate\/ecd11. Accessed 24 Jul 2026."},{"issue":"1","key":"1648_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-022-02122-z","volume":"11","author":"C Marshall","year":"2022","unstructured":"Marshall C, Sutton A, O\u2019Keefe H, Johnson E. The systematic review toolbox: keeping up to date with tools to support evidence synthesis. Syst Rev. 2022;11(1):245. https:\/\/doi.org\/10.1186\/s13643-022-02122-z.","journal-title":"Syst Rev"},{"issue":"1","key":"1648_CR41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.014","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3\u20139. https:\/\/doi.org\/10.1016\/j.jval.2021.11.014.","journal-title":"Value Health."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01648-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01648-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01648-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:07:29Z","timestamp":1785514049000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-026-01648-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":41,"alternative-id":["1648"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01648-7","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Allie B. Cichewicz, Kush Patel, and Kevin M. Kallmes are employed by and hold equity\u00a0in Nested Knowledge,\u00a0Inc., a commercial entity whose product is evaluated in the article. Lisa M. Bloudek and Sean D. Sullivan are employed by and hold equity in Curta, Inc., a paid subscriber to Nested Knowledge, Inc.\u2019s software.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Reports are available upon request.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by LB and AC. The first draft of the manuscript was written by LB and AC and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":7,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}